Valendo Health, a value-based endocrinology company focused on diabetes, announced $4 million in seed funding and a two-provider launch.
This company is Redesign Health aims to increase revenue for endocrinologists while helping them transition to a value-based care model.
We provide diabetes care clinician telemedicine and remote patient monitoring services, endocrinology-focused EMR, data analytics, and implementation assistance for value-based care contracts.
The Boston-based company partners with two providers: Cecelia Health is a national virtual specialty care provider for chronic care management, and Advanced Metabolic Care + Research is an endocrine center in Southern California serving patients with diabetes and other metabolic diseases.
“Our research shows that people with diabetes treated by endocrinologists are healthier and experience much better outcomes,” said Dave Terry, CEO and co-founder of Valendo Health. , many patients do not have access to specialized treatment.” Receive MobiHealthNews by email.
“Endocrinologists are among the lowest-paid medical specialists in the United States and face significant capacity constraints. At Valendo, we aim to improve clinical capabilities and grow practice revenue through virtual care and practice management support. Our mission is to help endocrinologists treat more people with diabetes and realize the immense value they create. It’s about getting paid based on.”
bigger trends
In 2021, 29.7 million people, or 8.9% of the U.S. population, had been diagnosed with diabetes.
Other companies focused on diabetes management include pharmaceutical giants Lilly launched LillyDirect earlier this year. The digital health experience gives patients with diabetes, obesity and migraines access to healthcare providers, educational information and a digital pharmacy of select Lilly Pharmaceuticals.
Last year, a Korean internet company Kakao Corporation has signed an agreement with Dexcom to establish a global digital diabetes management service. The partnership combines Kakao Healthcare's AI and software technology capabilities with Dexcom's continuous glucose monitoring (CGM) devices, the Dexcom G6 and G7.
